High-dose AMSA and bone marrow rescue in patients with solid tumors

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Solid tumors present a significant challenge in cancer treatment.
• High-dose chemotherapy regimens are explored to improve treatment outcomes.
• Autologous bone marrow rescue is a supportive care strategy in intensive chemotherapy.

Purpose of the Study:

• To assess the feasibility and toxicity of high-dose Amsacrine (AMSA) combined with autologous bone marrow rescue.
• To evaluate the preliminary efficacy of this treatment regimen in patients with solid tumors.

Main Methods:

• Seven patients with solid tumors received high-dose AMSA treatment.
• Treatment involved a total of 12 courses.
• Doses ranged from 600 to 1000 mg/m2 per course, followed by autologous bone marrow rescue.

Main Results:

• The primary toxicities observed were myelosuppression, fever of unknown origin, and stomatitis.
• One patient with malignant melanoma achieved stable disease for 2 months.
• The remaining six patients experienced progressive disease.

Conclusions:

• High-dose AMSA followed by autologous bone marrow rescue demonstrated significant toxicities.
• The regimen showed limited clinical benefit in this cohort of solid tumor patients.
• Further investigation into dose optimization or alternative regimens may be warranted.